Carles X. Raventós

Universitat Autònoma de Barcelona — Spain

Medicine · Health Sciences

22h-index1.9kcitations109works2.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(41), Prostate Cancer Treatment and Research(35), Urinary and Genital Oncology Studies(28), Prostate Cancer Diagnosis and Treatment(23), Urological Disorders and Treatments(20)

Publications109 total

Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review
Cancers·2025· 2 citedOpen Access
A multicenter study of perioperative and functional outcomes of open vs. robot assisted uretero-enteric reimplantation after radical cystectomy
World Journal of Urology·2025· 5 cited
Recovery of EndoAnchors Using a Four Loop Vascular Retriever Snare: Adaptive Solutions for Adverse Events Related to Endovascular Material
EJVES Vascular Forum·2025Open Access
O01 First-in-human study of TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
European Urology Open Science·2024Open Access
Comparison of Biomechanical Properties of the iCover and VBX Stent Grafts When Used as Bridge Stents in Fenestrated Endografts: An In Vitro Study
Journal of Endovascular Therapy·2024· 2 cited
ENLIGHTED phase 3 study: Efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) for treatment of low-grade upper tract urothelial cancer (LG UTUC).
Journal of Clinical Oncology·2024· 5 cited
PD48-02 FIRST SAFETY AND EFFICACY RESULTS OF THE TAR-210 ERDAFITINIB INTRAVESICAL DELIVERY SYSTEM IN PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER WITH SELECT <i>FGFR</i> ALTERATIONS
The Journal of Urology·2024· 6 cited
First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
European Urology·2024· 3 cited
Squamous cell carcinoma of the bladder and upper urinary tract (SCCBUT): a retrospective cohort analysis
European Urology Open Science·2023Open Access
LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
Annals of Oncology·2023· 28 citedOpen Access
Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
Cancers·2023· 5 citedOpen Access
[Optimization biomarkers in the surveillance of non muscle invasive bladder cancer.]
PubMed·2022· 2 cited
Perioperative and Functional Outcomes of Robot-assisted Ureteroenteric Reimplantation: A Multicenter Study of Seven Referral Institutions
European Urology Open Science·2022· 8 citedOpen Access
Evaluating the impact of the learning curve on the perioperative outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion
Actas Urológicas Españolas (English Edition)·2021· 5 cited
Análisis del impacto de la curva de aprendizaje de la cistectomía radical asistida por robot con derivación urinaria intracorpórea sobre los resultados perioperatorios
Actas Urológicas Españolas·2021· 3 cited
A Robot-Assisted Complete Urinary Tract Extirpation in a Patient with Simultaneous Panurothelial Carcinoma: A Case Report
Journal of Endourology Case Reports·2020· 1 citedOpen Access
Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review
BMC Urology·2020· 10 citedOpen Access
Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry
Actas Urológicas Españolas (English Edition)·2020
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
Cancer Treatment Reviews·2020· 29 cited
Terapia de privación de andrógenos en pacientes con enfermedad localizada: comparación de las opciones de tratamiento y tiempo hasta la resistencia a la castración. Resultados del Registro Español de Cáncer de Próstata
Actas Urológicas Españolas·2020· 4 cited
page 1 of 6Next →

Frequent Co-authors

Juan Moróte(37), Enrique Trilla(18), Anna Orsola(17), Jacques Planas(17), Lluís Cecchini(16), Fernando Lozano(12), G Encabo(9), Jaume Reventós(9), Albert Carrión(9), J.M. Abascal Junquera(7), Roberto Catalán(6), Inés de Torres(6), José A. Lorente(5), S. Esquena(5), Inés M. de Torres(4), Joan Palou(4), A. Piñero(4), José Fernando Jiménez Díaz(4), Isabel Trias(3), Ignacio Español(3)